These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

769 related articles for article (PubMed ID: 9210715)

  • 81. Is free/total PSA predictive of pathological stage and Gleason score in patients with prostate cancer and serum PSAPepe P; Panella P; Pietropaolo F; Pennisi M; Allegro R; Aragona F
    Urol Int; 2006; 76(3):232-5. PubMed ID: 16601385
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer.
    Björk T; Lilja H; Christensson A
    BJU Int; 1999 Dec; 84(9):1021-7. PubMed ID: 10571627
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays.
    Vessella RL; Lange PH; Partin AW; Chan DW; Sokoll LJ; Sasse EA; Crawford ED
    Urology; 2000 Jun; 55(6):909-14. PubMed ID: 10840107
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Influence of free-to-total prostate specific antigen variability on the early diagnosis of prostate cancer: a comparative study of three immunoassays.
    de la Taille A; Houlgatte A; Houdelette P; Goluboff ET; Berlizot P; Ricordel I
    Br J Urol; 1998 Sep; 82(3):389-92. PubMed ID: 9772876
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
    Becker C; Piironen T; Pettersson K; Hugosson J; Lilja H
    Urology; 2000 May; 55(5):694-9. PubMed ID: 10792083
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy.
    Ghavamian R; Blute ML; Bergstralh EJ; Slezak J; Zincke H
    Urology; 1999 Jul; 54(1):105-10. PubMed ID: 10414735
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Preoperative prostate-specific antigen in predicting pathologic stage and grade after radical prostatectomy.
    Winter HI; Bretton PR; Herr HW
    Urology; 1991 Sep; 38(3):202-5. PubMed ID: 1716021
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
    Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
    JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Relationships between total/free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia.
    Mao Q; Zheng X; Jia X; Wang Y; Qin J; Yang K; Bai Y; Xie L
    Int Urol Nephrol; 2009 Dec; 41(4):761-6. PubMed ID: 19224388
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
    Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ
    BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy.
    Wesseling S; Stephan C; Semjonow A; Lein M; Brux B; Sinha P; Loening SA; Jung K
    Clin Chem; 2003 Jun; 49(6 Pt 1):887-94. PubMed ID: 12765984
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
    Horn T; Krönke M; Rauscher I; Haller B; Robu S; Wester HJ; Schottelius M; van Leeuwen FWB; van der Poel HG; Heck M; Gschwend JE; Weber W; Eiber M; Maurer T
    Eur Urol; 2019 Oct; 76(4):517-523. PubMed ID: 30987843
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
    Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
    Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy.
    Tombal B; Querton M; de Nayer P; Sauvage P; Cosyns JP; Feyaerts A; Opsomer R; Wese FX; Van Cangh PJ
    Urology; 2002 Feb; 59(2):256-60. PubMed ID: 11834398
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution.
    Nan LB; Yin XT; Gao JP
    Med Sci Monit; 2019 Nov; 25():8345-8351. PubMed ID: 31691648
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Urology; 2000 May; 55(5):700-4. PubMed ID: 10792084
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men.
    Sakai I; Harada K; Hara I; Eto H; Miyake H
    Int J Clin Oncol; 2004 Feb; 9(1):64-7. PubMed ID: 15162829
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
    Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
    Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer.
    Pannek J; Subong EN; Jones KA; Marschke PL; Epstein JI; Chan DW; Carter HB; Luderer AA; Partin AW
    Urology; 1996 Dec; 48(6A Suppl):51-4. PubMed ID: 8973700
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer.
    Palisaar RJ; Graefen M; Karakiewicz PI; Hammerer PG; Huland E; Haese A; Fernandez S; Erbersdobler A; Henke RP; Huland H
    Eur Urol; 2002 Feb; 41(2):155-61. PubMed ID: 12074402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.